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incidence of infection in newborn infants has been related to these relative deficiencies, because complement is known to participate in the defense against bacterial and viral infections. The anaphylatoxins C3a, C4a, and C5a are known to mediate a series of b i o l o~c events. They induce histamine release from mast cells and -basophils, c a u k aggregation of granulocytes with subsequent enzyme liberation, and stimulate leukotriene synthesis (8, 9). Immune adherence, opsonization, leukocyte chemotaxis, and virus neutralization depend on activation of the complement system. In spite of this biologic importance, there are only a few studies on the complement system in the newborn infant. Studies on complement in newborn infants have shown a decreased concentration of the native proteins and low CH50 and APHSO activities compared with adults (10-13). There is little information in neonates about activation products of the complement cascade. Two recent studies report C3d levels (one ofthe final split products ofC3) in newborn infants with infection (14. IS).
The purpose of this study was to investigate activation of the complement system in the newborn infant to establish normal values for the activation products C3a-desArg, C3bBbP, and ClrsCI-inactivator and to determine their changes in infection of the neonate. C3a-desArg is generated by cleavage of C3. C3bBbP is an indicator of the alternative pathway activation ( 16) . and C I rsC I -inactivator is an indicator of classical pathway activation ( 17) .
MATERIALS AND METHODS
Purirnfs. Blood samples from 98 newborn infants were studied with the approval of the Department of Pediatrics Human Subjects Research Committee. Gestational age was derived from maternal history and confirmed by clinical assessment of maturity (18). Cultures of vagina and rectum to detect GBS were taken from all mothers during the last 10 wk of pregnancy. In the neonates. material for bacterial cultures was taken from the external ear and from gastric aspirate within the 1st h of life. Tracheal aspirates were taken from intubated infants. Clinical specimens were collected and inoculated onto the surface ofGBS agar (19) . In cases of premature rupture of the membranes or suspected maternal infection (fever, elevated CRP, leukocytosis), prenatal vaginal swabs and urine samples were also processed on chocolate and MacConkey agar for both gram-negative and gram-positive bacteria. Blood cultures were collected using the BCB system Liquoid Blood Culture Bottle BHI-S (F. HoffmannLa Roche AG, Basel, Switzerland). Thirty-two healthy neonates with gestational age between 36 and 42 wk and birth weight between 2500 and 4020 g were included in this study. Neither the mothers nor the infants were colonized with GBS or other potentially pathogenic bacteria, which had within the last few years been found to be the predominant pathogens for early onset neonatal sepsis in our perinatal care center. Forty-one healthy infants had mothers who were colonized with GBS. Fifteen newborns were colonized with GBS or gram-negative bacterial pathogens. Ten neonates had a severe early-onset infection with clinical manifestation at the I st d of life. The predominant clinical signs of infection were: respiratory distress, apnea, bradycardia, hypotonia, initability or lethargy, and impaired peripheral circulation. All the babies had two or more of the described clinical signs. All the babies developed CRP values 220 mg/L within the first 48 h of life. Nine of 10 babies suffered from culture-proven septicemia (Table 1) . One baby suffered from severe congenital pneumonia that led to ventilator-dependent respiratory distress. The focal infection was proven by the detection of GBS in the tracheal aspirate taken after intubation immediately after delivery. None of the babies suffered from perinatal asphyxia.
Plasma samples. EDTA plasma was obtained in all neonates within the first 6 h of life and frozen immediately at -70°C until assayed. Normal values for adults were obtained from healthy blood donors of the Blood Bank of the University of Heidelberg.
Measurement of complement proteins. Concentration of plasma C3 was determined by radial immunodiffusion (Behring Diagnostics, Frankfurt, Germany). C3a-desArg was quantitated as previously described (20) . Briefly, wells of polystyrene microtiter plates (Nunc, Roskilde, Denmark) were incubated with 100 pL of purified MAb H466 (10 pg/mL) in 0.01 M sodium phosphate, 0.15 M NaCI, pH 7.4 (buffer A). This capture antibody H466 reacts specifically with a neoantigenic determinant of C3a and does not recognize the uncleaved C3 molecule (2 1 ). Therefore, separation of C3a-desArg from C3 in the plasma sample before the assay was not necessary. After blocking of the remaining nonspecific binding sites with 0.5% casein (Merck. Darmstadt, Germany) in buffer A (1 h, 37"C), the patient sample (100 pL, diluted 1: 100 in buffer A containing 0.25% casein, 0.0 1 M EDTA, 0.05% Tween 20) was added and incubated for 1 h at room temperature. Bound C3a-desArg was detected by incubation with the second peroxidase-labeled MAb H 13 (22) followed by 100 pL/well of the peroxidase substrate ortho-phenylenediamine dihydrochloride (Dakopatts, Hamburg, Germany) in 0.1 M citric acid-phosphate buffer pH 5. The reaction was stopped after 5 min with 12.5% H2S04 (50 pL) and the O D measured by an ELISA reader (Easy Reader, SLT Labinstruments. Salzburg. Austria). C3a-desArg concentrations in the plasma samples were calculated from a calibration curve using different concentrations of purified C3a-desArg in EDTA plasma.
The complex C3bBbP was quantitated in a double-sandwich ELISA system (23) using 50 pL of goat anti-human P (Atlantic antibodies, Baxter, UnterschleiBheim, Germany) as capture antibody diluted 1:300 in buffer A. The remaining nonspecific binding sites were blocked with buffer A containing 0.25% BSA (buffer B, 2 h, room temperature). Fifty pL of patients' samples diluted 1:25 in sample buffer (buffer A containing 0.25% BSA, 0.01% EDTA, 0.05% Tween 20) were added and incubated ( I h, room temperature). Bound C3bBbP was detected with biotinylated anti-human C3c (Dakopatts) diluted 1:300 in buffer A, 0.05% Tween 20. Incubation with streptavidin-peroxidase (Amersham, Braunschweig. Germany) followed. and orthophenylenediamine dihydrochloride was used as substrate. The reaction was stopped with 12.5% H2S04, and OD was read at 490 nm. C3bBbP complex (U/mL) was calculated by reference to a standard curve obtained with serial dilutions of inulinactivated normal human serum. Quantitation of the ClrsCIinactivator complex (CIrsClina) (23) was done with rabbit antihuman Cl-inactivator (Dakopatts) as capture antibody (I: 100 in buffer A). After saturation of the plates with buffer B, plasma samples (diluted 1:500 in sample buffer) were added and incubated 1 h at room temperature. Goat anti-human CIS (Atlantic Antibodies, Baxter) diluted 1500 in sample buffer was used as second antibody followed by peroxidase-labeled rabbit anti-goat IgG (Dianova, Hamburg, Germany: 1500 in buffer B). 2,2'azinobis(3-ethylbenzthiazolinesulfonic acid) was used as substrate. The reaction was stopped with 0.2 M oxalic acid, and O D was read at 405 nm. Values were expressed as U/mL calculated by reference to a standard curve obtained with IgG-activated normal human serum. Each incubation step was followed by washing three times with buffer A containing 0.05% Tween 20.
All assays on complement activation products were done in duplicate, and a maximum of within-sample variance of 10% was accepted.
Statistical anaIy.~es. The significance of intergroup differences was assessed by the Mann-Whitney U-test. Statistically significant differences were accepted at p < 0.05. Data are expressed as median and range in the tables. Table 2 shows that C3 levels were similar in the four groups of neonates. This indicates that C3 was not affected by GBS colonization or septicemia. Healthy adults show C3 values of 0.8 to 1.2 g/L.
RESULTS
There were no significant differences in C3a-desArg levels between healthy newborn infants (I 77 + 101 pg/L) and a control group of normal adults (17 1 + 76 pg/L). Colonization of the mother or of the infant with GBS did not significantly affect C3a-desArg in the neonates. Three (9.4%) of the 32 healthy newborn infants (group I) had C3a-desArg levels >280 pg/L (mean 1 SD). Five of the 41 newborn infants (12.2%) with colonized mothers (group 11) and three of the 15 infants (20%) who were colonized themselves (group 111) had C3a-desArg >280 pg/L. In the infants with proven bacterial infection, an initial significant increase in C3a-desArg concentration was observed. Only one septic patient (patient 7 in Table 2 ) had a C3a-desArg level <280 pg/L. One neonate with a 10-fold elevation of C3a-desArg had severe early-onset infection. Table 2 shows the complement activation products C3bBbP (indicator of alternative pathway activation) and C 1 rsC 1 -inactivator (indicator of classical pathway activation) in the four groups. Concentrations of C3bBbP in GBS-colonized neonates and in infants with colonized mothers did not differ from that in newborns without colonization. However. neonates with proven infection showed a significant increase in C3bBbP levels ( p = 0.00 13). C I rsC I-inactivator levels did not differ among the four groups. There was a positive correlation ( r = 0.76) between C3adesArg levels and C3bBbP levels (Fig. I ), but there was no significant correlation between C3a-desArg and C l rsC 1 -inactivator ( r = 0.103) or C3 levels ( r = 0.136), indicating that C3a-desArg is activated via the alternative pathway independent of C3 concentration.
In the first few hours after birth, white blood cell counts, immature/total neutrophil counts, and differential blood cell counts showed no significant differences between the four groups ( Table 2) .
The values of C3, C3a-desArg, C3bBbP. and C l rsC I -inactivator in healthy neonates did not change significantly within the first 7 d after birth. Figure 2 gives an example of the course of C3a-desArg levels in one infant with severe early-onset infection under antibiotic treatment. CRP is shown as a comparison. The initial values represent a maximum for C3a-desArg and a considerable increase for CRP. On d 3. C3a-desArg decreased to only slightly elevated values, whereas CRP levels reached a maximum peak. C3bBbP levels showed an initial maximum peak and then decreased from d 3 to d 9 parallel to C3a-desArg levels. There were no significant changes in classical pathway activation.
DISCUSSION
Complement components are synthesized at an early stage of fetal development. In cord blood of full-term neonates. the concentrations of the components C 1. C2, C4, and C6 are about 50% of maternal levels (10. 24). Because levels of maternal complement rise during pregnancy, this corresponds to a higher percentage compared with normal adults (7). Plasma concentration of C7 in neonates is about 70% of the adult value (25) . and levels of C8 and C9 are about 10 to 25% of the value in normal adults (3). C3 levels in full-term neonates are about 50 to 75% of maternal levels (26, 27) or 60 to 80% of normal adults (28). In agreement with the decreased levels of various complement components. the CH50 (1.e. the functional activity of the classical pathway components) and APHSO in neonates are decreased to about 50% of the maternal values (26) .
It has been proposed that the reduced levels of complement components in neonates are a major cause for the enhanced susceptibility to infections, because complement is required for optimal chemotaxis (29) and opsonic activity (30. 3 I). However. measurements of the circulating native complement components or of the CH50 do not provide accurate information about the extent of complement activation, because both activation and reduced synthesis result in diminished levels of complement components. On the other hand. acute-phase reactions may lead to increased synthesis, thereby compensating for the consumption of complement components. Measurement of the complement-split product C3a-desArg and the complexes C3bBbP and C l rsC1 -inactivator by ELISA techniques provide a sensitive method of detecting complement activation. The levels of these proteins only depend on the degree of activation: they are not influenced by release or synthesis in an acute-phase reaction. This could be demonstrated by the level of C3 and its activation product C3a-desArg (Table 2) . Whereas C3 levels remained within the normal range even in severe early onset infection. the concentrations of C3a-desArg were significantly higher in these patients. C3 levels in the healthy neonates were lower than in adults (I), as reported previously (27.29). Studies of complement levels in neonatal infection gave conflicting results. Some authors
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neonates (Table I ) and in adults (23) . Moreover, severe neonatal infection increased C3a-desArg to the level observed in septi-40 cemic adults (23) . Thus, lower levels of the C3 component in neonates do not appear to limit the generation of C3a-desArg and C3bBbP.
The -E bacteria opsonizing them for subsequent phagocytosis. The small a peptides C3a and C5a can act as chemotactic factors. C5a attracts K neutrophils to the site of inflammation and stimulates them to release active mediators such as reactive oxygen metabolites, eicosanoids, and enzymes. The C5b-9 complex provides the lytic lo activity of complement. These events contribute to destruction of the intruders and provide an important and efficient mechanism of host defense. The apparently sufficient C3-activation does not, however, allow any conclusion on further functional o aspects. Zach et al. (39) reported defects in thiolester reactivity . Recently, it has been shown that supplemental C9 enhanced the capacity of neonatal sera to kill a pathogenic strain of Escherichia coli (40) , suggesting that C9 deficiency may be one of the factors that predispose neonates to develop E. coli -sepsis. Figure 2 and is in contradiction to the course of CRP, an acute-phase reactant that is used routinely. CRP showed a delayed increase that continued even after initiation of successful treatment, as previously shown in the literature (41) . This might be explained by the fact that the increase of CRP needs enhanced production of this protein, 0 which needs time, whereas complement activation products re- neonates with early-onset infection C3a-desArg was increased age-related changes. Pediatr Res 13: 1043 Res 13: -1046 within the first few hours of life ( 
